Abstract: Described are methods for vascular regeneration m a subject with peripheral vascular disease. Described are also methods of treating a wound. The methods can include administering an effective amount of an O-glycnacylation modifier agent described here. The method increases O-glycnacylation level in the wound compared to O-glycnacylation level without administration of an effective amount of an O-glycnacylation modifier agent.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: Disclosed are methods for imaging lumen-forming structures such as blood vessels using near-infrared fluorescence in the NIR-II region of 1000-1700 nm. The fluorescence is created by excitation of solubilized nano-structures that are delivered to the structures, such as carbon nanotubes, quantum dots or organic molecular fluorophores attached to hydrophilic polymers. These nanostructures fluoresce in the NIR-II region when illuminated through the skin and tissues. Fine anatomical vessel resolution down to ?30 ?m and high temporal resolution up to 5-10 frames per second is obtained for small-vessel imaging with up to 1 cm penetration depth in mouse hind limb, which compares favorably to tomographic imaging modalities such as CT and MRI with much higher spatial and temporal resolution, and compares favorably to scanning microscopic imaging techniques with much deeper penetration.

Abstract: Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: Disclosed are methods for imaging lumen-forming structures such as blood vessels using near-infrared fluorescence in the NIR-II region of 1000-1700 nm. The fluorescence is created by excitation of solubilized nano-structures that are delivered to the structures, such as carbon nanotubes, quantum dots or organic molecular fluorophores attached to hydrophilic polymers. These nanostructures fluoresce in the NIR-II region when illuminated through the skin and tissues. Fine anatomical vessel resolution down to ?30 ?m and high temporal resolution up to 5-10 frames per second is obtained for small-vessel imaging with up to 1 cm penetration depth in mouse hind limb, which compares favorably to tomographic imaging modalities such as CT and MRI with much higher spatial and temporal resolution, and compares favorably to scanning microscopic imaging techniques with much deeper penetration.

Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.

Abstract: The nuclear reprogramming of somatic cells with mRNA encoding reprogramming factors is shown to be greatly accelerated by activation of innate immune responses in the somatic cell. Methods of activating innate immunity include activation of PKR, of toll-like receptors, e.g. TLR3, etc. In some embodiments the mRNA provides the activator of innate immunity.

Abstract: The present disclosure provides DDAH modulators. Thus, the present disclosure provides a method of treating a patient suffering from a disorder characterized by excessive NO production and/or elevated DDAH activity, the method comprising administering to said patient an effective amount of a compound of one of formulae I-X. The present disclosure also provides a pharmaceutical composition comprising a compound of one of formulae I-X.

Abstract: Embodiments of the present invention relate to a therapeutic device (graft) comprising a collagen membrane having an aligned uniaxial or biaxial structure such that mammalian cells plated on the membrane align mainly along the direction of the collagen fibrils. In a further aspect, a graft comprising a substantially tubular body, wherein the body has an exterior surface, an interior surface, and at least one lumen extending therethrough such that a fluid flow through the lumen can direct mammalian cell migration. In a further aspect, mammalian cells or growth and angiogenic factors can be optionally attached to the exterior and/or interior surface of the substantially tubular body. In various aspects, the graft can be used as a vascular prosthesis, a stent, or a nerve regeneration scaffold. Methods of preparing and implanting same are also provided.

Abstract: Provided herein are diagnostic markers and uses thereof for predicting if a subject is at risk of a major adverse event. In particular, one aspect provided herein relates to methods to determine if a subject is at risk of having a major adverse effect by measuring at least 2, or at least 3 of the biomarkers beta 2 microglobulin, c-reactive protein and cystatin C.

Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

Abstract: The present invention provides ?2 microglobulin as a biomarker for qualifying or assessing peripheral artery disease in a subject.

Abstract: A bearing assembly includes an inner race adapted to be coupled to an inner member and an outer race adapted to be coupled to an outer member positioned such that the inner race is in an opposed and spaced apart relation from the outer race. Roller elements are disposed between the inner and outer races. An inner flange is coupled to the outer race, includes circumferentially spaced apart recesses and extends generally radially toward the inner race. An outer flange is coupled to the inner race. A flexible sealing member contacts both the inner flange and the outer flange. A shroud includes tabs that extend through the recesses. The tabs are coupled to the outer race. The inner and outer members are permitted to rotate relative to each other.

Abstract: Compositions and methods are provided for the cell-free synthesis of active reprogramming factor polypeptides. The reprogramming factors may be synthesized as fusion proteins comprising a permeant domain, such as polyarginme. The cell free-synthesis may be conducted at about 25 C in a bacterial cell extract from genetically alterd cells having decreased endogenous protease activity Further, the proteins may comprise a fusion partner which enhances solubility and may be refolded on a column.

Abstract: The present invention provides methods of modulating angiogenesis in an individual, as well as methods of identifying a candidate agent that modulates angiogenesis, where such methods involve modulating and identifying agents that modulate expression of gene products of a subset of genes concordantly-regulated by agonists of nicotinic acetylcholine receptor (nAChR), bFGF receptor, and VEGF receptor.